Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Tyrosine Kinase Inhibition: a New Perspective in the Fight against HIV.

Rodríguez-Mora S, Spivak AM, Szaniawski MA, López-Huertas MR, Alcamí J, Planelles V, Coiras M.

Curr HIV/AIDS Rep. 2019 Sep 11. doi: 10.1007/s11904-019-00462-5. [Epub ahead of print] Review.

PMID:
31506864
2.

IFI16 Targets the Transcription Factor Sp1 to Suppress HIV-1 Transcription and Latency Reactivation.

Hotter D, Bosso M, Jønsson KL, Krapp C, Stürzel CM, Das A, Littwitz-Salomon E, Berkhout B, Russ A, Wittmann S, Gramberg T, Zheng Y, Martins LJ, Planelles V, Jakobsen MR, Hahn BH, Dittmer U, Sauter D, Kirchhoff F.

Cell Host Microbe. 2019 Jun 12;25(6):858-872.e13. doi: 10.1016/j.chom.2019.05.002. Epub 2019 Jun 4.

PMID:
31175045
3.

Transcriptional Circuit Fragility Influences HIV Proviral Fate.

Morton EL, Forst CV, Zheng Y, DePaula-Silva AB, Ramirez NP, Planelles V, D'Orso I.

Cell Rep. 2019 Apr 2;27(1):154-171.e9. doi: 10.1016/j.celrep.2019.03.007.

4.

Sex Influences SAMHD1 Activity and Susceptibility to Human Immunodeficiency Virus-1 in Primary Human Macrophages.

Szaniawski MA, Spivak AM, Bosque A, Planelles V.

J Infect Dis. 2019 Feb 15;219(5):777-785. doi: 10.1093/infdis/jiy583.

PMID:
30299483
5.

Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.

Macedo AB, Novis CL, De Assis CM, Sorensen ES, Moszczynski P, Huang SH, Ren Y, Spivak AM, Jones RB, Planelles V, Bosque A.

JCI Insight. 2018 Oct 4;3(19). pii: 122673. doi: 10.1172/jci.insight.122673.

6.

Synthetic Ingenols Maximize Protein Kinase C-Induced HIV-1 Latency Reversal.

Spivak AM, Nell RA, Petersen M, Martins L, Sebahar P, Looper RE, Planelles V.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01361-18. doi: 10.1128/AAC.01361-18. Print 2018 Nov.

7.

Influence of Biological Sex, Age, and HIV Status in an In Vitro Primary Cell Model of HIV Latency Using a CXCR4 Tropic Virus.

Macedo AB, Resop RS, Martins LJ, Szaniawski MA, Sorensen ES, Spivak AM, Nixon DF, Jones RB, Planelles V, Bosque A.

AIDS Res Hum Retroviruses. 2018 Sep;34(9):769-777. doi: 10.1089/AID.2018.0098. Epub 2018 Aug 10.

8.

SAMHD1 Phosphorylation Coordinates the Anti-HIV-1 Response by Diverse Interferons and Tyrosine Kinase Inhibition.

Szaniawski MA, Spivak AM, Cox JE, Catrow JL, Hanley T, Williams ESCP, Tremblay MJ, Bosque A, Planelles V.

MBio. 2018 May 15;9(3). pii: e00819-18. doi: 10.1128/mBio.00819-18.

9.

CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells.

Abdel-Mohsen M, Kuri-Cervantes L, Grau-Exposito J, Spivak AM, Nell RA, Tomescu C, Vadrevu SK, Giron LB, Serra-Peinado C, Genescà M, Castellví J, Wu G, Del Rio Estrada PM, González-Navarro M, Lynn K, King CT, Vemula S, Cox K, Wan Y, Li Q, Mounzer K, Kostman J, Frank I, Paiardini M, Hazuda D, Reyes-Terán G, Richman D, Howell B, Tebas P, Martinez-Picado J, Planelles V, Buzon MJ, Betts MR, Montaner LJ.

Sci Transl Med. 2018 Apr 18;10(437). pii: eaar6759. doi: 10.1126/scitranslmed.aar6759.

10.

Novel Latency Reversal Agents for HIV-1 Cure.

Spivak AM, Planelles V.

Annu Rev Med. 2018 Jan 29;69:421-436. doi: 10.1146/annurev-med-052716-031710. Epub 2017 Nov 3. Review.

11.

Mycobacterium tuberculosis reactivates latent HIV-1 in T cells in vitro.

Larson EC, Novis CL, Martins LJ, Macedo AB, Kimball KE, Bosque A, Planelles V, Barrows LR.

PLoS One. 2017 Sep 26;12(9):e0185162. doi: 10.1371/journal.pone.0185162. eCollection 2017.

12.

When DNA damage is acceptable.

Planelles V.

Cell Cycle. 2017 Jun 3;16(11):1020-1021. doi: 10.1080/15384101.2017.1324125. Epub 2017 May 19. No abstract available.

13.

Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation.

Bosque A, Nilson KA, Macedo AB, Spivak AM, Archin NM, Van Wagoner RM, Martins LJ, Novis CL, Szaniawski MA, Ireland CM, Margolis DM, Price DH, Planelles V.

Cell Rep. 2017 Jan 31;18(5):1324-1334. doi: 10.1016/j.celrep.2017.01.022.

14.

Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo.

Spivak AM, Larragoite ET, Coletti ML, Macedo AB, Martins LJ, Bosque A, Planelles V.

Retrovirology. 2016 Dec 20;13(1):88. doi: 10.1186/s12977-016-0319-0.

15.

Transcriptomic Analysis Implicates the p53 Signaling Pathway in the Establishment of HIV-1 Latency in Central Memory CD4 T Cells in an In Vitro Model.

White CH, Moesker B, Beliakova-Bethell N, Martins LJ, Spina CA, Margolis DM, Richman DD, Planelles V, Bosque A, Woelk CH.

PLoS Pathog. 2016 Nov 29;12(11):e1006026. doi: 10.1371/journal.ppat.1006026. eCollection 2016 Nov.

16.

HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function.

Garrido C, Spivak AM, Soriano-Sarabia N, Checkley MA, Barker E, Karn J, Planelles V, Margolis DM.

Front Immunol. 2016 Sep 21;7:356. eCollection 2016.

17.

Macrophage Cell Coinfected with HIV-1 and H37Ra.

Larson EC, Pond CD, Szaniawski MA, Martins LJ, Planelles V, Barrows LR.

AIDS Res Hum Retroviruses. 2016 Dec;32(12):1171-1172. Epub 2016 Jun 16. No abstract available.

18.

CD155 on HIV-Infected Cells Is Not Modulated by HIV-1 Vpu and Nef but Synergizes with NKG2D Ligands to Trigger NK Cell Lysis of Autologous Primary HIV-Infected Cells.

Davis ZB, Sowrirajan B, Cogswell A, Ward JP, Planelles V, Barker E.

AIDS Res Hum Retroviruses. 2017 Feb;33(2):93-100. doi: 10.1089/AID.2015.0375. Epub 2016 Jul 20.

19.

HIV Integration Site Analysis of Cellular Models of HIV Latency with a Probe-Enriched Next-Generation Sequencing Assay.

Sunshine S, Kirchner R, Amr SS, Mansur L, Shakhbatyan R, Kim M, Bosque A, Siliciano RF, Planelles V, Hofmann O, Ho Sui S, Li JZ.

J Virol. 2016 Apr 14;90(9):4511-4519. doi: 10.1128/JVI.01617-15. Print 2016 May.

20.

A Conserved HIV-1-Derived Peptide Presented by HLA-E Renders Infected T-cells Highly Susceptible to Attack by NKG2A/CD94-Bearing Natural Killer Cells.

Davis ZB, Cogswell A, Scott H, Mertsching A, Boucau J, Wambua D, Le Gall S, Planelles V, Campbell KS, Barker E.

PLoS Pathog. 2016 Feb 1;12(2):e1005421. doi: 10.1371/journal.ppat.1005421. eCollection 2016 Feb.

21.

HIV-1 Eradication: Early Trials (and Tribulations).

Spivak AM, Planelles V.

Trends Mol Med. 2016 Jan;22(1):10-27. doi: 10.1016/j.molmed.2015.11.004. Epub 2015 Dec 12. Review.

22.

Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex.

Saayman SM, Lazar DC, Scott TA, Hart JR, Takahashi M, Burnett JC, Planelles V, Morris KV, Weinberg MS.

Mol Ther. 2016 Mar;24(3):488-98. doi: 10.1038/mt.2015.202. Epub 2015 Nov 19.

23.

BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency.

Pache L, Dutra MS, Spivak AM, Marlett JM, Murry JP, Hwang Y, Maestre AM, Manganaro L, Vamos M, Teriete P, Martins LJ, König R, Simon V, Bosque A, Fernandez-Sesma A, Cosford ND, Bushman FD, Young JA, Planelles V, Chanda SK.

Cell Host Microbe. 2015 Sep 9;18(3):345-53. doi: 10.1016/j.chom.2015.08.009.

24.

An Ounce of Tat Prevention Is Worth a Pound of Functional Cure.

Planelles V.

MBio. 2015 Aug 18;6(4). pii: e01269-15. doi: 10.1128/mBio.01269-15. No abstract available.

25.

HIV-1 Vpu utilizes both cullin-RING ligase (CRL) dependent and independent mechanisms to downmodulate host proteins.

Ramirez PW, DePaula-Silva AB, Szaniawski M, Barker E, Bosque A, Planelles V.

Retrovirology. 2015 Jul 28;12:65. doi: 10.1186/s12977-015-0192-2.

26.

Modeling HIV-1 Latency in Primary T Cells Using a Replication-Competent Virus.

Martins LJ, Bonczkowski P, Spivak AM, De Spiegelaere W, Novis CL, DePaula-Silva AB, Malatinkova E, Trypsteen W, Bosque A, Vanderkerckhove L, Planelles V.

AIDS Res Hum Retroviruses. 2016 Feb;32(2):187-93. doi: 10.1089/aid.2015.0106. Epub 2015 Jul 14.

27.

Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.

Spivak AM, Bosque A, Balch AH, Smyth D, Martins L, Planelles V.

Antimicrob Agents Chemother. 2015 Oct;59(10):5984-91. doi: 10.1128/AAC.01077-15. Epub 2015 Jul 13.

28.

Determinants for degradation of SAMHD1, Mus81 and induction of G2 arrest in HIV-1 Vpr and SIVagm Vpr.

DePaula-Silva AB, Cassiday PA, Chumley J, Bosque A, Monteiro-Filho CMR, Mahon CS, Cone KR, Krogan N, Elde NC, Planelles V.

Virology. 2015 Mar;477:10-17. doi: 10.1016/j.virol.2014.12.040. Epub 2015 Jan 22.

29.

Understanding the molecular manipulation of DCAF1 by the lentiviral accessory proteins Vpr and Vpx.

Cassiday PA, DePaula-Silva AB, Chumley J, Ward J, Barker E, Planelles V.

Virology. 2015 Feb;476:19-25. doi: 10.1016/j.virol.2014.11.024. Epub 2014 Dec 11.

30.

Sulfonation pathway inhibitors block reactivation of latent HIV-1.

Murry JP, Godoy J, Mukim A, Swann J, Bruce JW, Ahlquist P, Bosque A, Planelles V, Spina CA, Young JA.

Virology. 2014 Dec;471-473:1-12. doi: 10.1016/j.virol.2014.08.016. Epub 2014 Oct 11.

31.

Replication competent virus as an important source of bias in HIV latency models utilizing single round viral constructs.

Bonczkowski P, De Spiegelaere W, Bosque A, White CH, Van Nuffel A, Malatinkova E, Kiselinova M, Trypsteen W, Witkowski W, Vermeire J, Verhasselt B, Martins L, Woelk CH, Planelles V, Vandekerckhove L.

Retrovirology. 2014 Aug 21;11:70. doi: 10.1186/s12977-014-0070-3.

32.

Downmodulation of CCR7 by HIV-1 Vpu results in impaired migration and chemotactic signaling within CD4⁺ T cells.

Ramirez PW, Famiglietti M, Sowrirajan B, DePaula-Silva AB, Rodesch C, Barker E, Bosque A, Planelles V.

Cell Rep. 2014 Jun 26;7(6):2019-30. doi: 10.1016/j.celrep.2014.05.015. Epub 2014 Jun 5.

33.

An HIV-encoded antisense long noncoding RNA epigenetically regulates viral transcription.

Saayman S, Ackley A, Turner AW, Famiglietti M, Bosque A, Clemson M, Planelles V, Morris KV.

Mol Ther. 2014 Jun;22(6):1164-1175. doi: 10.1038/mt.2014.29. Epub 2014 Feb 28.

34.

Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro.

Gavegnano C, Detorio M, Montero C, Bosque A, Planelles V, Schinazi RF.

Antimicrob Agents Chemother. 2014;58(4):1977-86. doi: 10.1128/AAC.02496-13. Epub 2014 Jan 13.

35.

An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients.

Spina CA, Anderson J, Archin NM, Bosque A, Chan J, Famiglietti M, Greene WC, Kashuba A, Lewin SR, Margolis DM, Mau M, Ruelas D, Saleh S, Shirakawa K, Siliciano RF, Singhania A, Soto PC, Terry VH, Verdin E, Woelk C, Wooden S, Xing S, Planelles V.

PLoS Pathog. 2013;9(12):e1003834. doi: 10.1371/journal.ppat.1003834. Epub 2013 Dec 26.

36.

Reactivation of latent HIV-1 in central memory CD4⁺ T cells through TLR-1/2 stimulation.

Novis CL, Archin NM, Buzon MJ, Verdin E, Round JL, Lichterfeld M, Margolis DM, Planelles V, Bosque A.

Retrovirology. 2013 Oct 24;10:119. doi: 10.1186/1742-4690-10-119.

37.

Kinase control of latent HIV-1 infection: PIM-1 kinase as a major contributor to HIV-1 reactivation.

Duverger A, Wolschendorf F, Anderson JC, Wagner F, Bosque A, Shishido T, Jones J, Planelles V, Willey C, Cron RQ, Kutsch O.

J Virol. 2014 Jan;88(1):364-76. doi: 10.1128/JVI.02682-13. Epub 2013 Oct 23.

38.

HIV latency and integration site placement in five cell-based models.

Sherrill-Mix S, Lewinski MK, Famiglietti M, Bosque A, Malani N, Ocwieja KE, Berry CC, Looney D, Shan L, Agosto LM, Pace MJ, Siliciano RF, O'Doherty U, Guatelli J, Planelles V, Bushman FD.

Retrovirology. 2013 Aug 16;10:90. doi: 10.1186/1742-4690-10-90.

39.

BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism.

Boehm D, Calvanese V, Dar RD, Xing S, Schroeder S, Martins L, Aull K, Li PC, Planelles V, Bradner JE, Zhou MM, Siliciano RF, Weinberger L, Verdin E, Ott M.

Cell Cycle. 2013 Feb 1;12(3):452-62. doi: 10.4161/cc.23309. Epub 2012 Feb 1.

40.

Cyclin T1 and CDK9 T-loop phosphorylation are downregulated during establishment of HIV-1 latency in primary resting memory CD4+ T cells.

Budhiraja S, Famiglietti M, Bosque A, Planelles V, Rice AP.

J Virol. 2013 Jan;87(2):1211-20. doi: 10.1128/JVI.02413-12. Epub 2012 Nov 14.

41.

Differential effects of Vpr on single-cycle and spreading HIV-1 infections in CD4+ T-cells and dendritic cells.

de Silva S, Planelles V, Wu L.

PLoS One. 2012;7(5):e35385. doi: 10.1371/journal.pone.0035385. Epub 2012 May 3.

42.

Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-κB activity.

Wolschendorf F, Bosque A, Shishido T, Duverger A, Jones J, Planelles V, Kutsch O.

J Virol. 2012 Apr;86(8):4548-58. doi: 10.1128/JVI.06726-11. Epub 2012 Feb 15.

43.

SAMHD1 Joins the red Queen's court.

Planelles V.

Cell Host Microbe. 2012 Feb 16;11(2):103-5. doi: 10.1016/j.chom.2012.02.001.

44.

Facts and fiction: cellular models for high throughput screening for HIV-1 reactivating drugs.

Planelles V, Wolschendorf F, Kutsch O.

Curr HIV Res. 2011 Dec 1;9(8):568-78. Review.

45.

Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells.

Bosque A, Famiglietti M, Weyrich AS, Goulston C, Planelles V.

PLoS Pathog. 2011 Oct;7(10):e1002288. doi: 10.1371/journal.ppat.1002288. Epub 2011 Oct 6.

46.

Restricted access to myeloid cells explained.

Planelles V.

Viruses. 2011 Sep;3(9):1624-33. doi: 10.3390/v3091624. Epub 2011 Sep 5.

47.

Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu.

Shah AH, Sowrirajan B, Davis ZB, Ward JP, Campbell EM, Planelles V, Barker E.

Cell Host Microbe. 2010 Nov 18;8(5):397-409. doi: 10.1016/j.chom.2010.10.008.

48.

Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells.

Bosque A, Planelles V.

Methods. 2011 Jan;53(1):54-61. doi: 10.1016/j.ymeth.2010.10.002. Epub 2010 Oct 21. Review.

49.

Roles of Vpr and Vpx in modulating the virus-host cell relationship.

Planelles V, Barker E.

Mol Aspects Med. 2010 Oct;31(5):398-406. doi: 10.1016/j.mam.2010.05.002. Epub 2010 Jun 15. Review.

50.

Vpr and its interactions with cellular proteins.

Planelles V, Benichou S.

Curr Top Microbiol Immunol. 2009;339:177-200. doi: 10.1007/978-3-642-02175-6_9. Review.

PMID:
20012529

Supplemental Content

Loading ...
Support Center